https://www.selleckchem.com/pr....oducts/apo866-fk866.
As best responses, 3 patients had partial responses and 3 achieved stable disease. Patients were followed for ≥17 months; progression-free survival ranged from 3 to 15 months, and overall survival ranged from 4 to 17 months. CONCLUSION These 7 cases provide real-world data for the use of lenvatinib plus everolimus in patients with mRCC with primary resistance to first-line VEGF-targeted TKIs or ICI combination therapy. INTRODUCTION In 31 to 75 percent of cases, errors in laboratory medicine have preanalytical causes such as erroneo
Like
Comment
Share
